Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTP-Hib联合疫苗
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTP-Hib联合疫苗 (DTP-Hib combination vaccine) is an adsorbed, quadrivalent combination vaccine candidate under development by AIM Vaccine (specifically through its subsidiary AIM Kanghuai Biopharmaceutical, also known as AIM Action BioPharm). The vaccine is designed to induce protective immunity against diphtheria, tetanus, pertussis, and invasive infections caused by Haemophilus influenzae type b (Hib). By combining antigens for these four major childhood diseases into a single formulation, the vaccine aims to significantly reduce the number of injections required for infants and young children, thereby improving vaccination compliance and convenience for parents. The vaccine is currently in preclinical development, with clinical trial applications (IND) planned.
- Other names
- DTP-Hib combination vaccineDTP-Hib疫苗Diphtheria-tetanus-pertussis-Hib combination vaccine吸附无细胞百白破b型流感嗜血杆菌(DTP-Hib)联合疫苗吸附无细胞百白破b型流感嗜血杆菌联合疫苗多联疫苗
02
Targets
Diphtheria toxoidHib conjugate (Haemophilus influenzae type b capsular polysaccharide-protein conjugate)
Beyond the preview
Go deeper on DTP-Hib联合疫苗.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTP-Hib联合疫苗.